Targeting Therapeutically Resistant HER2+ Breast Cancers

Alexander Schaffer, MRHS

Abstract

Mammary Carcinomas are one of the leading causes of cancer. In 20% of these cancers, the cause is related to an overexpression of the Erb-B2 gene, leading to an excess of the HER2 protein. Treatments are available; however, these treatments tend to see a therapeutic resistant recurrence. A novel target, target A, has shown to overcome this resistance. By treating HER2+ cells with inhibitor A and studying the effects with PCR, IHC, and Western Blotting, the resistance can be overcome: limiting cell proliferation and increasing cell apoptosis.

 
Apr 14th, 9:30 AM

Targeting Therapeutically Resistant HER2+ Breast Cancers

Neville theater

Mammary Carcinomas are one of the leading causes of cancer. In 20% of these cancers, the cause is related to an overexpression of the Erb-B2 gene, leading to an excess of the HER2 protein. Treatments are available; however, these treatments tend to see a therapeutic resistant recurrence. A novel target, target A, has shown to overcome this resistance. By treating HER2+ cells with inhibitor A and studying the effects with PCR, IHC, and Western Blotting, the resistance can be overcome: limiting cell proliferation and increasing cell apoptosis.